Evidence map›Paper›PMID 40496072›Full record

ArticleJournal of pharmaceutical analysis2025

Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling.

Yifei He, Chenggu Zhu, Peng Lei, Chen Yang, Yifan Zhang, Yuandong Zheng, Xingxing Diao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Evolving CRBN ligands enhance the drug-like properties of protein degraders.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yifei HeShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Chenggu ZhuWuxi Beita Pharmatech Co., Ltd., Wuxi, Jiangsu, 214437, China.
Peng LeiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Chen YangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Yifan ZhangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Yuandong ZhengShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Xingxing DiaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteolysis-targeting chimeras (PROTACs) represent a promising class of drugs that can target disease-causing proteins more effectively than traditional small molecule inhibitors can, potentially revolutionizing drug discovery and treatment strategies. However, the links between

Indexed as

In vitro–in vivo extrapolation (IVIVE)Physiologically based pharmacokinetic (PBPK) modelPROTACRadiolabelingVepdegestrant (ARV-471)

Identifiers

PMID40496072
PMCPMC12151198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.